(MedPage Today) -- Injectable corticosteroids must now carry a new label warning about the risks of severe adverse effects from epidural injections including death, stroke, and permanent blindness and paralysis, the FDA said.
(MedPage Today) -- What was your biggest struggle with health information technology and how did you overcome it? We posed that question to Peter Elias, MD, as part of a new MedPage Today question-and-answer series featuring leaders in health IT.
(MedPage Today) -- A mumps outbreak in Ohio continues to grow, while MERS has claimed a high-profile victim in Saudi Arabia. Also, three major pharmaceutical companies are mixing and matching units.
(MedPage Today) -- A novel formulation of a standard myeloma therapy met the safety-related primary endpoints of a phase II trial, according to the manufacturer.
(MedPage Today) -- Despite being called a "willful infringer" of patents held by Edwards Lifesciences, Medtronic will be allowed to continue selling its CoreValve transcatheter aortic valve as legal wrangling continues.
(MedPage Today) -- Where do neurostimulators belong in the treatment of headaches? Three well-known specialists said the approved devices appear safe and effective, while research is still ongoing with more invasive approaches that hold promise for currently intractable headaches.
(MedPage Today) -- Psychological effects of false-positive mammograms, an association between trisomy-21 and malignancy, and favorable results from an ovarian cancer trial have all made news recently.
(MedPage Today) -- An FDA advisory committee has voted unanimously against approval of an oral combination of morphine and oxycodone (Moxduo) for acute pain.
(MedPage Today) -- Patients with unruptured arteriovenous malformations (AVMs) in the brain appeared to fare better over the long term by following a conservative strategy and avoiding interventions, a nonrandomized, observational study suggested.
(MedPage Today) -- Diazepam proved equal to lorazepam for effectiveness and safety in treating children with status epilepticus, surprising the randomized trial's investigators and others in the field.